NCT02238756

Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: CureVac · Industry
• Sex: Male
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.

Conditions

• Rabies

Interventions

Type	Name	Description
BIOLOGICAL	CV8102	Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
BIOLOGICAL	Rabipur	Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
BIOLOGICAL	CV8102 + Rabipur	Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-09-01
• Completion: 2016-11-01
• First posted: 2014-09-12
• Last updated: 2018-06-06

Locations

1 site across 1 country: Germany